Acadia names Mark Schneyer permanent CFO; previously interim CFO since Sept 2021

ACADIA PHARMACEUTICALS INC

Mark Schneyer appointed EVP, CFO effective Dec 9, 2021; had served as interim CFO since Sept 2021.
Schneyer previously SVP, Business Development and CBO; joined Acadia from Pfizer in May 2020.
He led the Dec 2020 acquisition of CerSci Therapeutics, adding a Phase 2-ready pain program.
Schneyer retains responsibility for business development and investor relations; reports to CEO Steve Davis.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark C. Schneyer

Executive Vice President, Chief Financial Officer

ACAD · ACADIA PHARMACEUTICALS INC

Effective: 2021-12-09
Filed: December 14, 2021, 6:59 PM ET

On December 9, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Mark C. Schneyer as Executive Vice President, Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark C. Schneyer was appointed as Executive Vice President, Chief Financial Officer at ACADIA PHARMACEUTICALS INC.

Action: appointed
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On December 9, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Mark C. Schneyer as Executive Vice President, Chief Financial Officer.

View on SEC.gov

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-21-356869

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.